ASPIRE
To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke or death from any cause in patients with recent ICH and atrial fibrillation. Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.